Skip to content
Disclosery

Rosalind Advisors, Inc.

Follow

13F filer, CIK 1622627, TORONTO, Ontario, Canada

Rosalind Advisors, Inc. reported $284,527,096 across 42 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-12. Its ten largest share positions make up 62.94% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001622627-26-000011

Period
2025-12-31
Reported value
$285M
Holdings
42
Top 10 weight
62.94%
New
11
Sold out
8

Largest buys vs the previous quarter

SecurityShares changeApprox. value
REPLnew+1,410,497$13.7M
AVBPnew+215,871$4.34M
XFORadded+1,061,313$4.25M
FENCadded+536,668$4.13M
PROFadded+376,770$2.97M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RZLTexited-1,807,202-$17M
CYTKreduced-204,955-$13M
VERONA PHARMA PLCexited-100,000-$10.7M
GUTSreduced-4,614,269-$10.2M
IDYAexited-350,000-$9.52M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001622627-26-000011, largest first. % of portfolio is the value over $274,464,181, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
DCTHDELCATH SYS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,650,389 shares; 2024Q4: 2,650,389 shares; 2025Q1: 2,900,389 shares; 2025Q2: 3,300,389 shares; 2025Q3: 3,300,389 shares; 2025Q4: 3,300,389 shares 3,300,389$33M12.02%02026-10-13, Form 4: converted 3,627 shares on 2026-10-13 Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,654,944 shares; 2025Q1: 2,654,944 shares; 2025Q2: 2,654,944 shares; 2025Q3: 4,000,000 shares; 2025Q4: 3,403,721 shares 3,403,721$20.5M7.48%-596,279Timeline
FENCFENNEC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,259,876 shares; 2025Q1: 1,782,844 shares; 2025Q2: 2,045,644 shares; 2025Q3: 2,076,840 shares; 2025Q4: 2,613,508 shares 2,613,508$20.1M7.33%+536,668Timeline
XERSXERIS BIOPHARMA HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,104,995 shares; 2024Q4: 3,104,995 shares; 2025Q1: 2,495,986 shares; 2025Q2: 2,155,594 shares; 2025Q3: 1,795,766 shares; 2025Q4: 2,111,700 shares 2,111,700$16.6M6.04%+315,934Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 595,000 shares; 2025Q2: 700,000 shares; 2025Q3: 600,000 shares; 2025Q4: 450,000 shares 450,000$14M5.1%-150,000Timeline
MDWDMEDIWOUND LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 628,050 shares; 2024Q4: 628,050 shares; 2025Q1: 506,893 shares; 2025Q2: 407,061 shares; 2025Q3: 749,054 shares; 2025Q4: 749,054 shares 749,054$13.8M5.04%0Timeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 900,000 shares; 2025Q1: 2,644,517 shares; 2025Q2: 2,043,563 shares; 2025Q3: 1,929,563 shares; 2025Q4: 1,788,475 shares 1,788,475$13.8M5.03%-141,088Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 260,000 shares; 2025Q1: 850,000 shares; 2025Q2: 900,000 shares; 2025Q3: not reported; 2025Q4: 1,410,497 shares 1,410,497$13.7M5%newTimeline
ATYRATYR PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,039,080 shares; 2025Q4: 1,039,080 shares 1,039,080$13.6M4.96%0Timeline
HELPCYBIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 810,918 shares; 2025Q1: 810,918 shares; 2025Q2: 810,918 shares; 2025Q3: 1,500,000 shares; 2025Q4: 1,657,540 shares 1,657,540$13.6M4.94%+157,540Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 650,000 shares; 2025Q4: 690,000 shares 690,000$12.6M4.59%+40,000Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 192,974 shares; 2025Q3: 300,000 shares; 2025Q4: 300,000 shares 300,000$12.5M4.54%0Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 400,000 shares; 2025Q3: 400,000 shares; 2025Q4: 195,045 shares 195,045$12.4M4.52%-204,955Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,544,607 shares; 2025Q4: 2,605,920 shares 2,605,920$10.4M3.8%+1,061,313Timeline
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 420,000 shares; 2025Q2: 420,000 shares; 2025Q3: 750,000 shares; 2025Q4: 750,000 shares 750,000$10M3.66%0
PROFPROFOUND MED CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 485,973 shares; 2024Q4: 692,185 shares; 2025Q1: 692,185 shares; 2025Q2: 692,185 shares; 2025Q3: 692,185 shares; 2025Q4: 1,068,955 shares 1,068,955$8.41M3.07%+376,770Timeline
NSPRINSPIREMD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,514,046 shares; 2024Q4: 2,495,783 shares; 2025Q1: 2,274,990 shares; 2025Q2: 2,289,099 shares; 2025Q3: 3,905,743 shares; 2025Q4: 3,905,743 shares 3,905,743$6.95M2.53%0Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 885,000 shares; 2024Q4: 1,128,700 shares; 2025Q1: 1,218,700 shares; 2025Q2: 1,218,700 shares; 2025Q3: 400,000 shares; 2025Q4: 400,000 shares 400,000$4.86M1.77%0Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 215,871 shares 215,871$4.34M1.58%newTimeline
TLPHTALPHERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 758,966 shares; 2024Q4: 613,939 shares; 2025Q1: 2,003,939 shares; 2025Q2: 2,003,939 shares; 2025Q3: 4,385,757 shares; 2025Q4: 3,579,273 shares 3,579,273$4.08M1.49%-806,484Timeline
MYOMYOMO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,021,391 shares; 2024Q4: 2,998,945 shares; 2025Q1: 2,703,661 shares; 2025Q2: 3,595,788 shares; 2025Q3: 3,790,788 shares; 2025Q4: 3,839,772 shares 3,839,772$3.49M1.27%+48,984Timeline
PYPDPOLYPID LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 679,168 shares; 2024Q4: 1,018,021 shares; 2025Q1: 1,018,021 shares; 2025Q2: 975,462 shares; 2025Q3: 918,668 shares; 2025Q4: 696,556 shares 696,556$3.02M1.1%-222,112Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 730,488 shares 730,488$2.12M0.77%newTimeline
RGNTREGENTIS BIOMATERIALS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 251,510 shares 251,510$1.7M0.62%newTimeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 750,000 shares; 2024Q4: 1,062,500 shares; 2025Q1: 612,901 shares; 2025Q2: 300,000 shares; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares 100,000$1.25M0.46%0Timeline
NRXSNEURAXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 286,138 shares 286,138$1.04M0.38%newTimeline
KURAKURA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 100,000 shares; 2025Q2: 100,000 shares; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares 100,000$1.04M0.38%0Timeline
GUTSFRACTYL HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 5,000,000 shares; 2025Q4: 385,731 shares 385,731$849K0.31%-4,614,269Timeline
BFRIBIOFRONTERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 495,490 shares; 2024Q4: 811,918 shares; 2025Q1: 644,393 shares; 2025Q2: 976,448 shares; 2025Q3: 1,140,764 shares; 2025Q4: 1,140,764 shares 1,140,764$650K0.24%0Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
INVESCO QQQ TRINVESCO QQQ TR PUTput450,000$3.03M+200,000
STATE STR SPDR S&P 500 ETF TSTATE STR SPDR S&P 500 ETF T PUTput510,000$1.89M+210,000
ANAVEX LIFE SCIENCES CORPANAVEX LIFE SCIENCES CORP PUTput1,168,600$1.88Mnew
SPDR SERIES TRUSTSPDR SERIES TRUST PUTput1,937,600$1.35M-190,700
ISHARES TRISHARES TR PUTput200,000$1.11M0
ARRIVENT BIOPHARMA INCARRIVENT BIOPHARMA INC COMcall107,900$540Knew
VERASTEM INCVERASTEM INC COM NEWcall268,600$160K-377,900
UNIQURE NVUNIQURE NV CALLcall100,000$95Knew
REPLIMUNE GROUP INCREPLIMUNE GROUP INC CALLcall230,900$11.5K-280,500
VIKING THERAPEUTICS INCVIKING THERAPEUTICS INC CALLcall100,000$2Knew
REZOLUTE INCREZOLUTE INC CALLcall263,100$00
REPLIMUNE GROUP INCREPLIMUNE GROUP INC COMput264,700$0new
VISTAGEN THERAPEUTICS INCVISTAGEN THERAPEUTICS INC COMcall493,400$0new

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RZLTREZOLUTE INC1,807,202$17Mshares
VERONA PHARMA PLCVERONA PHARMA PLC100,000$10.7Mshares
IDYAIDEAYA BIOSCIENCES INC350,000$9.52Mshares
QUREUNIQURE NV125,000$7.3Mshares
ATYR PHARMA INCATYR PHARMA INC1,570,200$4.47Mput
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INC1,542,520$1.11Mshares
IDEAYA BIOSCIENCES INCIDEAYA BIOSCIENCES INC35,900$237Kcall
SCHOLAR ROCK HLDG CORPSCHOLAR ROCK HLDG CORP100,000$10Kput

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001622627-26-000011 base2026-02-12acceptance time not in the bulk data set